CA3085572A1 - Bispecific antibody to a-syn/igf1r and use thereof - Google Patents

Bispecific antibody to a-syn/igf1r and use thereof Download PDF

Info

Publication number
CA3085572A1
CA3085572A1 CA3085572A CA3085572A CA3085572A1 CA 3085572 A1 CA3085572 A1 CA 3085572A1 CA 3085572 A CA3085572 A CA 3085572A CA 3085572 A CA3085572 A CA 3085572A CA 3085572 A1 CA3085572 A1 CA 3085572A1
Authority
CA
Canada
Prior art keywords
seq
amino acid
acid sequence
nos
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3085572A
Other languages
English (en)
French (fr)
Inventor
Jinhyung Ahn
Sungwon AN
Dongin Kim
Eunsil SUNG
Jaehyun EOM
Sang Hoon Lee
Weonkyoo YOU
Juhee Kim
Kyungjin PARK
Hyejin Chung
Jinwon JUNG
Bora Lee
Byungje Sung
Yeunju KIM
Yong-Gyu Son
Seawon AHN
Daehae SONG
Jiseon YOO
Youngdon PAK
Donghoon YEOM
Yoseob LEE
Jaeho Jung
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ABL Bio Inc
Original Assignee
Ahn Seawon
An Sungwon
Chung Hyejin
Eom Jaehyun
Kim Yeunju
Lee Yoseob
Pak Youngdon
Park Kyungjin
Son Yong Gyu
Song Daehae
Sung Eunsil
Yeom Donghoon
Yoo Jiseon
You Weonkyoo
ABL Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ahn Seawon, An Sungwon, Chung Hyejin, Eom Jaehyun, Kim Yeunju, Lee Yoseob, Pak Youngdon, Park Kyungjin, Son Yong Gyu, Song Daehae, Sung Eunsil, Yeom Donghoon, Yoo Jiseon, You Weonkyoo, ABL Bio Inc filed Critical Ahn Seawon
Publication of CA3085572A1 publication Critical patent/CA3085572A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Psychology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA3085572A 2017-12-14 2018-12-14 Bispecific antibody to a-syn/igf1r and use thereof Pending CA3085572A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
KR10-2017-0172205 2017-12-14
KR20170172205 2017-12-14
US201862693474P 2018-07-03 2018-07-03
US62/693,474 2018-07-03
US201862734388P 2018-09-21 2018-09-21
US201862734391P 2018-09-21 2018-09-21
US62/734,388 2018-09-21
US62/734,391 2018-09-21
PCT/KR2018/015953 WO2019117684A1 (ko) 2017-12-14 2018-12-14 a-syn/IGF1R에 대한 이중 특이 항체 및 그 용도

Publications (1)

Publication Number Publication Date
CA3085572A1 true CA3085572A1 (en) 2019-06-20

Family

ID=66819361

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3085572A Pending CA3085572A1 (en) 2017-12-14 2018-12-14 Bispecific antibody to a-syn/igf1r and use thereof

Country Status (9)

Country Link
US (2) US12071483B1 (https=)
EP (2) EP3725806A4 (https=)
JP (5) JP7212391B2 (https=)
KR (1) KR102263812B1 (https=)
CN (2) CN111886251A (https=)
AU (2) AU2018385230B2 (https=)
BR (1) BR112020011875A2 (https=)
CA (1) CA3085572A1 (https=)
WO (2) WO2019117685A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3567054A4 (en) * 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
CA3051839A1 (en) 2017-02-17 2018-08-23 Bristol-Myers Squibb Company Antibodies to alpha-synuclein and uses thereof
KR102508933B1 (ko) * 2017-11-17 2023-03-13 에이비엘바이오 주식회사 알파-시누클레인에 대한 항체 및 그 용도
EP3725806A4 (en) * 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
US12473342B2 (en) * 2018-04-27 2025-11-18 The Trustees Of The University Of Pennsylvania Chimeric antigen receptor T regulatory cells for the treatment of atherosclerosis
EP4268842A3 (en) * 2019-06-14 2024-05-22 ABL Bio, Inc. BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF
CA3163017A1 (en) * 2019-12-26 2021-07-01 Daehae SONG Method for purifying biologically active peptide by using protein a affinity chromatography
US20250304709A1 (en) * 2022-05-05 2025-10-02 Eli Lilly And Company Multispecific binding molecules and methods of use thereof
WO2026029176A1 (ja) * 2024-08-01 2026-02-05 株式会社抗体医学研究所 抗インテグリンα８β１抗体
CN118805740B (zh) * 2024-08-07 2025-12-19 中国中医科学院中药研究所 一种人呼吸道合胞病毒感染小鼠重症肺炎动物模型的构建方法和应用

Family Cites Families (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en) 1983-11-01 1988-11-17 Terumo Corp Pharmaceutical composition containing urokinase
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
WO1996033735A1 (en) 1995-04-27 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991018982A1 (en) 1990-06-05 1991-12-12 Immunex Corporation Type ii interleukin-1 receptors
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
US5470582A (en) 1992-02-07 1995-11-28 Syntex (U.S.A.) Inc. Controlled delivery of pharmaceuticals from preformed porous polymeric microparticles
ES2301158T3 (es) 1992-07-24 2008-06-16 Amgen Fremont Inc. Produccion de anticuerpos xenogenicos.
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
CA2196496A1 (en) 1997-01-31 1998-07-31 Stephen William Watson Michnick Protein fragment complementation assay for the detection of protein-protein interactions
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
ME00502B (me) 2001-01-05 2011-10-10 Amgen Fremont Inc Antitjela za insulinu sličan receptor faktora i rasta
US20050026823A1 (en) 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
DE602004029581D1 (de) 2003-08-13 2010-11-25 Pfizer Prod Inc Modifizierte humane igf-1r antikörper
FR2873699B1 (fr) 2004-07-29 2009-08-21 Pierre Fabre Medicament Sa Nouveaux anticorps anti igf ir rt leurs utilisations
EA013752B1 (ru) 2004-08-09 2010-06-30 Элан Фармасьютикалз, Инк. Предупреждение и лечение синуклеинопатических и амилоидогенных заболеваний
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
CA2612449A1 (en) 2005-06-17 2006-12-28 Imclone Systems Incorporated Receptor antagonists for treatment of metastatic bone cancer
WO2007042289A2 (en) * 2005-10-11 2007-04-19 Ablynx N.V. Nanobodies™ and polypeptides against egfr and igf-ir
CA2625681C (en) 2005-10-12 2016-08-02 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human cd38
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
AR064464A1 (es) * 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
US20110014117A1 (en) * 2007-06-28 2011-01-20 Schering Corporation Anti-igf1r
CN102164960A (zh) * 2008-09-26 2011-08-24 罗氏格黎卡特股份公司 双特异性抗-egfr/抗-igf-1r抗体
NZ597692A (en) 2008-12-12 2013-08-30 Boehringer Ingelheim Int Anti-IGF antibodies
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
CN102307935B (zh) 2008-12-23 2017-06-09 3M创新有限公司 无定形微孔有机硅酸盐组合物
UY32808A (es) * 2009-07-29 2011-02-28 Abbott Lab Inmunoglobulinas como dominio variable dual y usos de las mismas
JP5894939B2 (ja) 2010-02-26 2016-03-30 バイオアークティック ニューロサイエンス アーベー プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用
EP2366714A1 (en) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein
CA2818173C (en) 2010-11-30 2022-05-03 Genentech, Inc. Low affinity blood brain barrier receptor antibodies and uses therefor
SI2723379T1 (sl) 2011-06-23 2019-03-29 Biogen International Neuroscience Gmbh Molekule, ki se vežejo ma anti alfa-sinuklein
RS63930B1 (sr) 2011-10-28 2023-02-28 Prothena Biosciences Ltd Humanizovana antitela koja prepoznaju alfa-sinuklein
BR112014010664A2 (pt) 2011-11-02 2017-04-25 Biogen Idec Int Neuroscience Gmbh uso de um anticorpo anti-alfa-sinucleína para diagnosticar um nível elevado de alfa-sinucleína no cérebro
DK2807188T3 (da) * 2012-01-27 2019-10-07 Prothena Biosciences Ltd Humaniserede antistoffer, der genkender alpha-synuclein
HUE045144T2 (hu) 2012-08-29 2019-12-30 Hoffmann La Roche Véragygát-shuttle
UA118441C2 (uk) * 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
EP2906596B1 (en) 2012-10-12 2023-12-27 Arizona Board of Regents on behalf of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
US9534044B2 (en) 2013-02-28 2017-01-03 United Arab Emirates University Alpha-synuclein antibodies and uses thereof
KR20140138533A (ko) * 2013-05-24 2014-12-04 한화케미칼 주식회사 항 igf-1r 단일클론 항체 및 이를 포함하는 암치료용 조성물
US20150093399A1 (en) 2013-08-28 2015-04-02 Bioasis Technologies, Inc. Cns-targeted conjugates having modified fc regions and methods of use thereof
JP2017501848A (ja) 2013-11-19 2017-01-19 プロセナ バイオサイエンシーズ リミテッド 便秘症状からのレビー小体病の免疫療法のモニター
LT3071597T (lt) * 2013-11-21 2020-10-12 F. Hoffmann-La Roche Ag Antikūnai prieš alfa-sunukleiną ir jų naudojimo būdai
US9629801B2 (en) 2014-01-10 2017-04-25 Wisconsin Alumni Research Foundation Blood-brain barrier targeting antibodies
KR101906558B1 (ko) * 2014-02-28 2018-10-11 (재) 스크립스코리아항체연구원 Tspan8에 특이적인 신규 항체 및 이의 용도
NZ724869A (en) * 2014-03-06 2022-07-01 Nat Res Council Canada Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
DK3114141T3 (da) * 2014-03-06 2020-08-10 Nat Res Council Canada Insulinlignende vækstfaktor 1-receptor-specifikke antistoffer og anvendelse deraf
PE20170088A1 (es) 2014-03-06 2017-03-09 Nat Res Council Canada Anticuerpos especificos del receptor del factor 1 de crecimiento similar a la insulina y usos de los mismos
CA2944402A1 (en) * 2014-04-08 2015-10-15 Prothena Biosciences Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
JP2017536102A (ja) 2014-10-16 2017-12-07 ジェネンテック， インコーポレイテッド 抗アルファ−シヌクレイン抗体及び使用方法
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
BR112019013953A2 (pt) 2017-01-06 2020-02-11 Abl Bio Inc. Anticorpo anti-a-syn e uso do mesmo
EP3567054A4 (en) 2017-01-06 2021-03-10 ABL Bio Inc. ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF
EP3625258A1 (en) 2017-05-16 2020-03-25 Alector LLC Anti-siglec-5 antibodies and methods of use thereof
EP3661961A4 (en) 2017-08-02 2021-04-14 Stressmarq Biosciences Inc. ANTIBODIES BINDING TO ACTIVE ALPHA-SYNUCLEIN
KR102508933B1 (ko) 2017-11-17 2023-03-13 에이비엘바이오 주식회사 알파-시누클레인에 대한 항체 및 그 용도
EP3725806A4 (en) 2017-12-14 2022-03-30 ABL Bio Inc. BISPECIFIC ANTIBODIES AGAINST A-SYN/IGF1R AND ASSOCIATED USE
EP4268842A3 (en) 2019-06-14 2024-05-22 ABL Bio, Inc. BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF
TW202309076A (zh) 2021-05-12 2023-03-01 南韓商Ａｂｌ生物公司 用於治療α-突觸核蛋白病之抗體

Also Published As

Publication number Publication date
JP2024096805A (ja) 2024-07-17
AU2022241522A1 (en) 2022-12-22
KR20200067838A (ko) 2020-06-12
JP2022104966A (ja) 2022-07-12
KR102263812B1 (ko) 2021-06-14
EP3725806A1 (en) 2020-10-21
JP2021506770A (ja) 2021-02-22
JP7806138B2 (ja) 2026-01-26
WO2019117684A1 (ko) 2019-06-20
JP7212391B2 (ja) 2023-01-25
EP4403218A2 (en) 2024-07-24
JP2023052217A (ja) 2023-04-11
CN116731173A (zh) 2023-09-12
CN111886251A (zh) 2020-11-03
EP4403218A3 (en) 2024-11-06
JP7513651B2 (ja) 2024-07-09
AU2022241522B2 (en) 2025-02-20
AU2018385230A1 (en) 2020-07-02
EP3725806A4 (en) 2022-03-30
WO2019117685A3 (ko) 2019-08-01
US20240101687A1 (en) 2024-03-28
US12071483B1 (en) 2024-08-27
JP2024156657A (ja) 2024-11-06
JP7625305B2 (ja) 2025-02-03
AU2018385230B2 (en) 2022-10-13
WO2019117685A2 (ko) 2019-06-20
BR112020011875A2 (pt) 2020-11-24

Similar Documents

Publication Publication Date Title
AU2022241522B2 (en) Bispecific antibody to a-syn/igf1r and use thereof
CA2921639A1 (en) Cd70-binding peptides and method, process and use relating thereto
AU2023202595B2 (en) BISPECIFIC ANTIBODY AGAINST a-SYN/IGF1R AND USE THEREOF
EA047717B1 (ru) БИСПЕЦИФИЧНОЕ АНТИТЕЛО К α-SYN/IGF1R И ЕГО ПРИМЕНЕНИЕ
EA045348B1 (ru) БИСПЕЦИФИЧНОЕ АНТИТЕЛО К α-SYN/IGF1R И ЕГО ПРИМЕНЕНИЕ
HK40073718A (en) Bispecific antibody against a-syn/igf1r and use thereof
BR122025025877A2 (pt) ANTICORPO BISPECÍFICO AO alfa-SYN/IGF1R E USO DO MESMO
HK40032661A (en) Bispecific antibody to a-syn/igf1r and use thereof
EA047682B1 (ru) БИСПЕЦИФИЧЕСКОЕ АНТИТЕЛО К α-SYN/IGF1R И ЕГО ПРИМЕНЕНИЕ
EA050076B1 (ru) Антитело к igf1r и его применение

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20200611

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20240926

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD

Year of fee payment: 6

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241125

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241125

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241125

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241212

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250207

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250218

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250218

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250710

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250710

D11 Substantive examination requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D11-D131 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (RCE) RECEIVED

Effective date: 20251110

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20251110

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251117

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251117

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D174 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251231

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D148 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR CONTINUED EXAMINATION (NOA/CNOA) DETERMINED COMPLIANT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260108